Open AccessEffect of telmisartan on histological activity and fibrosis of non-alcoholic steatohepatitis: A 1-year randomized control trial
Author(s) -
Shahinul Alam,
J. Kabir,
Golam Mustafa,
UtpalDas Gupta,
Sajid Hasan,
AKMKhorshed Alam
Publication year - 2016
Publication title -
the saudi journal of gastroenterology/saudi journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.608
H-Index - 32
eISSN - 1998-4049
pISSN - 1319-3767
DOI - 10.4103/1319-3767.173762
Subject(s) - medicine , telmisartan , gastroenterology , fibrosis , steatohepatitis , fatty liver , metabolic syndrome , steatosis , odds ratio , insulin resistance , randomized controlled trial , confidence interval , disease , insulin , blood pressure , obesity
Telmisartan can attenuate two hit pathogenesis of non-alcoholic steatohepatitis (NASH). This study aimed to observe the effect of Telmisartan on non-alcoholic fatty liver disease (NAFLD) activity score (NAS) and fibrosis score in NASH patients.